This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Print Page   |   Contact Us   |   Sign In   |   Register
Community Search
CMC BWG Case Study
Share |

A consortium of the companies shown above, collectively known as the CMC-Biotech Working Group (CMC-BWG), has prepared a case study on the development of a monoclonal antibody. To view the entire case study please click here. The case study is intended to stimulate discussion between regulatory authorities and industry on the application of Quality by Design to products of biotechnology. CASSS has joined forces with the individuals of the consortium to promote and disseminate the case study.
The case study is not a mock submission, nor a gold standard defining the content of future regulatory submissions, and is not intended to be reviewed for approvability. The case study presents some novel ideas, and aspirational approaches that could be achieved when the principles of QbD are fully embraced.  This marks a significant opportunity to expand the discussion in the biotechnology community on the implementation of the advanced concepts of QbD. 
In addition to highlighting the case study here on our web site, we have plans to use it extensively around the world in discussions with industry and regulators throughout 2010 and beyond.  Look for sessions in the programs of the CMC Forum Europe (April 2010) and CMC Strategy Forum (July 2010) as well other workshops to be announced focusing on the A-Mab Case Study.


more Calendar

9/28/2020 » 10/1/2020
CE Pharm 2020

10/13/2020 » 10/15/2020
CMC Strategy Forum North America Fall 2020

Membership Software Powered by YourMembership  ::  Legal